Form 4: Humacyte Director Todd Pope Granted 80,000 Stock Options

Humacyte, Inc. Director Todd Pope was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Summary

• Todd Pope, a Director of Humacyte, Inc. (HUMA), was granted 80,000 stock options.
• The transaction date for this grant was June 12, 2025.
• Each option has an exercise price of $2.41.
• The options are for the right to buy 80,000 shares of Humacyte Common Stock.
• The options will expire on June 12, 2035.
• The vesting schedule dictates that the first 25% of the options become exercisable on June 12, 2026.
• Following the initial vesting, 1/48th of the total option grant will become exercisable on the 12th of each month through June 12, 2029.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is generally a neutral to slightly positive event as it aligns management interests with shareholders, without indicating any immediate financial performance changes.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• This type of equity compensation is a standard practice to attract and retain experienced board members.

Future Outlook

The vesting schedule for the granted stock options indicates a commitment period for Director Todd Pope, with options becoming exercisable incrementally through June 2029, aligning his long-term interests with the company's performance.

Management Comments

• The filing was signed by Todd Pope by Dale A. Sander as Attorney-in-Fact.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director. Such grants are common practice across industries to incentivize and retain key personnel, aligning their interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The grant of 80,000 stock options to Todd Pope, a Director of Humacyte, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's incentives with shareholder value creation, potentially leading to better long-term performance.

Next Steps

• The stock options will begin to vest on June 12, 2026, with subsequent monthly vesting through June 12, 2029.
• Todd Pope may choose to exercise the vested options at any time before their expiration on June 12, 2035.

Key Dates

Keywords

Humacyte, HUMA, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Vesting Schedule